New England IRB will be closed on Friday, July 3rd.
The Friday submission deadline for Boards A and B will be extended until 12:00 noon on Monday, July 6th.
New England IRB is an independent institutional review board for sponsors, CROs and individual researchers across
the U.S. Our priority is to ensure safety of human subjects in clinical trials, and we are committed to an ethical and thorough
review process.
Our Boards are comprised of highly qualified members with significant experience and knowledge in the ethical,
scientific and legal aspects of clinical trials.
New England IRB reviews:
- All Phases of FDA regulated clinical trials (Phase 1 - Phase IV)
- Drug, device and biologic studies
- Registry studies
- Peri-approval and post-approval studies
- Socio-behavioral and educational studies
- Requests for Exemption<
Founded in 1988, New England IRB was one of the first central IRBs established to meet the ethical review needs of the
clinical trials industry. For studies ranging from one site to several thousand, NEIRB is focused on the protection of human subjects,
responsiveness and service.
We offer responsive review timelines while maintaining mechanisms to ensure a thorough, duly diligent, high quality
review.
- Three review Boards
- Protocol review within one week of receipt of complete application
- 24-48 hour site review upon receipt of complete application
- Results conveyed the day following review
Our secure web portal and electronic systems are helpful tools that create efficiencies in submissions and notifications.
New England IRB has been audited by the United States Food and Drug Administration, and found to be in compliance with
regulations. We are qualified to serve as the IRB for federally funded research.
Please contact New England IRB if you would like to arrange for a review. If you need further information, please feel
free to call 781-431-7577 or email info@neirb.com.
|
